Table 1.

Indicators used in interview study

Indicator topic	Indicator details
Risky prescribing	Avoidance of the following prescribing combinations:
	• Prescribing of a traditional oral NSAID or low-dose aspirin in patients with a history of peptic ulceration WITHOUT co-prescription of a gastro-protective drug.
	• Prescribing of a traditional oral NSAID in patients aged 75 or over WITHOUT co-prescription of a gastro-protective drug.
	• Prescribing of a traditional oral NSAID and aspirin in patients aged 65 or over WITHOUT co-prescription of a gastro-protective drug.
	• Prescribing of aspirin and clopidogrel in patients aged 65 or over WITHOUT co-prescription of a gastro-protective drug.
	• Prescribing of warfarin and a traditional oral NSAID WITHOUT co-prescription of a gastro-protective drug.
	• Prescribing of warfarin and low-dose aspirin or clopidogrel, WITHOUT co-prescription of a gastro-protective drug.
	• Prescribing an oral NSAID in patients with heart failure.
	• Prescribing an oral NSAID in patients prescribed both a diuretic and an ACE-inhibitor / ARB.
	• Prescribing an oral NSAID in patients with chronic kidney disease (stages 3, 4 and 5)
Treatment targets in type 2 diabetes	Achievement of all three recommended levels:
	• Blood pressure below 140/80 mmHg (or 130/80 mmHg if there is kidney, eye or cerebrovascular damage).
	• HbA1c value below or equal to 59 mmol/mol.
	• Cholesterol level below or equal to ≤ 4.0 mmol/l in patients who are 40 or older.
Blood pressure targets in treated hypertension	Aim for a target clinic blood pressure below 140/90 mmHg in people aged under 80 years with treated hypertension.
	Aim for a target clinic blood pressure below 150/90 mmHg in people aged 80 years and over with treated hypertension.
Anticoagulation in atrial fibrillation	In patients with atrial fibrillation who are either post-stroke, or have had a transient ischaemic attack:
	• Warfarin should be administered as the most effective thromboprophylactic agent.
	• Aspirin or dipyridamole should not be administered as thromboprophylactic agents unless indicated for the treatment of comorbidities or vascular disease.
	Those patients with AF in whom there is a record of a CHADS2 (congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke) score of 1 should be offered anticoagulation drug therapy or anti-platelet therapy.
	Those patients with AF whose latest record of a CHADS2 score is greater than 1 should be offered anticoagulation therapy.